Afamelanotide
FDA-approved product (implant, subcutaneous), marketed as Scenesse.
- Registered studies
- 23
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Erythropoietic protoporphyria
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Protectives against uv-radiation for systemic use
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA65.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli62.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae25.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis66.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
23registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Afamelanotide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Trimetrexate GlucuronateExisting use: Other agents against amoebiasis and other protozoal diseases88.6% AI-predicted activityagainst E. coliLab records exist17 registered studies
- Folic AcidExisting use: Acne, Anemia, Anemia (phenotype) and 8 more87.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more86.8% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- PralatrexateExisting use: Cancer, Mature T-cell and NK-cell non-Hodgkin lymphoma, Neoplasm and 2 more82.2% AI-predicted activityagainst E. coli44 registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives81.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Leucovorin CalciumExisting use: Osteosarcoma67.6% AI-predicted activityagainst E. coli50+ registered studies
- LevoleucovorinExisting use: Anemia, Colorectal adenocarcinoma, Colorectal cancer and 3 more67.6% AI-predicted activityagainst E. coli50+ registered studies
- PyrimethamineExisting use: Malaria, Toxoplasmosis64.6% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Copanlisib DihydrochlorideExisting use: Follicular lymphoma, Neoplasm, Neoplasm of mature B-cells63.5% AI-predicted activityagainst E. coli10 registered studies
- Rimegepant SulfateExisting use: Migraine disorder61.6% AI-predicted activityagainst E. coli50+ registered studies
- Histrelin AcetateExisting use: Neoplasm, Prostate adenocarcinoma, Prostate cancer61.6% AI-predicted activityagainst E. coli13 registered studies
- Pafolacianine SodiumExisting use: Other diagnostic agents61.4% AI-predicted activityagainst E. coli1 registered study
Registered studies
A registration describes a study; it does not establish a positive result.
Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP)
NCT01097044 · start 2010-04
Registered record
- Registry ID
- NCT01097044
- Conditions
- Erythropoietic Protoporphyria
- Interventions
- Afamelanotide; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2010-04
- Completion
- 2011-04
- Enrolment
- 77
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErythropoietic ProtoporphyriaInterventionAfamelanotide; PlaceboPhasePhase 2Registry statusCompletedPhase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)
NCT00979745 · start 2009-09
Registered record
- Registry ID
- NCT00979745
- Conditions
- Erythropoietic Protoporphyria
- Interventions
- Afamelanotide; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2009-09
- Completion
- 2011-05
- Enrolment
- 74
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErythropoietic ProtoporphyriaInterventionAfamelanotide; PlaceboPhasePhase 3Registry statusCompletedImplant Pharmacokinetic and Pharmacodynamic Study
NCT03634137 · start 2009-09
Registered record
- Registry ID
- NCT03634137
- Conditions
- Healthy
- Interventions
- Afamelanotide Group 1; Afamelanotide Group 2
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2009-09
- Completion
- 2010-03
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionAfamelanotide Group 1; Afamelanotide Group 2PhasePhase 1Registry statusCompletedPhase II Solar Urticaria (SU) Pilot Study
NCT00859534 · start 2008-12
Registered record
- Registry ID
- NCT00859534
- Conditions
- Solar Urticaria
- Interventions
- afamelanotide
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2008-12
- Completion
- 2009-07
- Enrolment
- 5
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSolar UrticariaInterventionafamelanotidePhasePhase 2Registry statusCompletedAfamelanotide as Adjunctive Therapy in Patients Undergoing Photodynamic Therapy (PDT) Utilising Porfimer Sodium
NCT04425746 · start 2008-08-05
Registered record
- Registry ID
- NCT04425746
- Conditions
- Patients Undergoing Photodynamic Therapy Using Porfimer Sodium
- Interventions
- Afamelanotide; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2008-08-05
- Completion
- 2009-05-28
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPatients Undergoing Photodynamic Therapy Using Porfimer SodiumInterventionAfamelanotide; PlaceboPhasePhase 2Registry statusCompletedPhase II AK Study in Organ Transplant Patients
NCT00829192 · start 2007-11
Registered record
- Registry ID
- NCT00829192
- Conditions
- Actinic Keratoses; Carcinoma, Squamous Cell; Organ Transplant Recipients
- Interventions
- Afamelanotide (CUV1647); Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Unknown
- Start
- 2007-11
- Completion
- 2012-08
- Enrolment
- 200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionActinic Keratoses; Carcinoma, Squamous Cell; Organ Transplant RecipientsInterventionAfamelanotide (CUV1647); PlaceboPhasePhase 2Registry statusUnknownPhase III Trial of CUV1647 in Polymorphic Light Eruption (PLE)
NCT00472901 · start 2007-05
Registered record
- Registry ID
- NCT00472901
- Conditions
- Polymorphic Light Eruption (PLE)
- Interventions
- Afamelanotide (CUV1647)
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2007-05
- Completion
- 2010-09
- Enrolment
- 18
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPolymorphic Light Eruption (PLE)InterventionAfamelanotide (CUV1647)PhaseNot recordedRegistry statusCompletedMulticentre Phase III Erythropoietic Protoporphyria Study
NCT04053270 · start 2007-05
Registered record
- Registry ID
- NCT04053270
- Conditions
- Erythropoietic Protoporphyria
- Interventions
- Afamelanotide; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2007-05
- Completion
- 2009-12-09
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErythropoietic ProtoporphyriaInterventionAfamelanotide; PlaceboPhasePhase 3Registry statusCompleted